Oxford Vaccine Could Reduce Spread in UK

The United Kingdom had administered the first dose of the Oxford-AstraZeneca vaccine to 9.6 million people by 3 February 2021. While this was only 14.4% of the total population, people were already asking how long before positive results come in. Scientists at various universities around the world simulated the likely outcome based on the Stage 3 trial results. Their findings confirm the Oxford vaccine may indeed reduce spread in the UK.

UK Politicians Put a More Positive Spin On This

UK Health Secretary Matt Hancock could scarcely contain his enthusiasm when he spoke to national broadcaster BBC. ‘Vaccines are a way out of this pandemic,’ he exclaimed. The study findings were ‘absolutely superb’, he added. His comments echoed the conclusion in the report summary, which reads as follows:

Main Conclusion of Report

‘ChAdOx1 nCoV-19 vaccination programs aimed at vaccinating a large proportion of the population with a single dose – with a second dose given after a 3 month period – are an effective strategy for reducing disease. And may be the optimal for rollout of a pandemic vaccine when supplies are limited in the short term.’

Oxford Vaccine Might Reduce Spread in UK Twofold

If the Oxford-AstraZeneca vaccine proves as effective in practice, then each person receiving it will also protect other people. This supports the assumption a rapid reduction in transmission will follow the nation-wide inoculation. However, the final result will depend on how many people in the UK ultimately agree to receive the vaccine and that’s still an unknown.

But the conclusion that the Oxford vaccine could reduce spread in the UK depends on data for the original strain. The national broadcaster asked Prof Andrew Pollard, chief investigator of the Oxford vaccine trial about the new Kent variant. The Prof replied he was awaiting research findings. However, he predicted ‘good protection’ and promised to publish results soon.